Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 164,677 | 211,007 | 178,875 | 1,176,096 | 213,172 |
| Cost of Goods | 6,950 | 15,781 | 11,420 | 12,862 | 16,283 |
| Gross Profit | 157,727 | 195,226 | 167,455 | 1,163,234 | 196,889 |
| Operating Expenses | 230,026 | 192,991 | 202,832 | 193,871 | 359,561 |
| Operating Income | -71,349 | 3,016 | -34,957 | 970,225 | -162,389 |
| Interest Expense | 55,188 | 32,592 | 30,358 | 34,092 | 41,060 |
| Other Income | -12,546 | 6,502 | -5,737 | -6,305 | 108,750 |
| Pre-tax Income | -139,083 | -23,074 | -71,052 | 929,828 | -94,699 |
| Income Tax | -4,118 | -38,970 | -6,203 | 63,266 | -28,813 |
| Net Income Continuous | -134,965 | 15,896 | -64,849 | 866,562 | -65,886 |
| Net Income | $-134,965 | $15,896 | $-64,849 | $866,562 | $-65,886 |
| EPS Basic Total Ops | -1.88 | 0.20 | -0.83 | 11.09 | -0.85 |
| EPS Basic Continuous Ops | -1.88 | 0.20 | -0.83 | 11.09 | -0.85 |
| EPS Diluted Total Ops | -1.63 | 0.20 | -0.83 | 10.04 | -0.85 |
| EPS Diluted Continuous Ops | -1.65 | 0.18 | -0.83 | 10.03 | -0.85 |
| EPS Diluted Before Non-Recurring Items | -1.67 | 0.20 | -0.83 | 10.04 | -0.24 |
| EBITDA(a) | $-63,184 | $8,228 | $-31,529 | $975,432 | $1,648 |